{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T05:43:28Z","timestamp":1698903808463},"posted":{"date-parts":[[2023,4,17]]},"group-title":"In Review","reference-count":15,"publisher":"Research Square Platform LLC","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,4,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n        <jats:p><jats:bold>Background &amp; Aim:<\/jats:bold> Since The emergence of the COVID-19, patients with cancer have been among the most vulnerable patients, as this infection can be severe and mostly requires intensive care therapy. Literature discussing the risk factors and the outcome of these patients in intensive care units (ICU) is accumulating. Our study aims to search for the incidence of COVID-19 infection in cancer patients and analyses their associated comorbidities, possible risk factor for infections, and their outcomes.\n<jats:bold>Methods: <\/jats:bold>Patients with active cancer under treatment and those recently diagnosed with cancer and had confirmed COVID-19 infection requiring ICU admission were included in our study over 8 months, from March to October 2022. Patient demographic data, comorbidities, ICU stay, duration of hospital stay, oxygenation\/ventilatory requirements, treatment, secondary bacterial infection, and outcome were collected from the COVID-19 patients' registry in the ICU. Data were entered into the SPSS program version 23, and results were considered statistically significant at p \u2264 0.05.\n<jats:bold>Results:  <\/jats:bold>A total of 24 patients with cancer and COVID-19 infection required intensive care therapy. The most common type of malignancy in those patients was solid organ tumor (13 vs. 11 patients), and most of the study sample were males (20\/ 83.3%). Seventy-five percent (18 patients) required intubation and invasive ventilation. Twenty-nine percent (7 patients) had secondary bacterial pneumonia and bacteremia. In addition, 70% had septic shock and required vasopressors. Acute kidney injury (AKI) due to rhabdomyolysis (P&lt;0.001), secondary bacterial infection (P&lt;0.006), bacteremia and pneumonia (P&lt;0.02), invasive ventilation (P&lt;0.02) and requiring muscle relaxant (P&lt;0.02), the requirement for High flow nasal cannula and prone position (P&lt;0.03 and 0.01) respectively, shock (P&lt;0.004) were significantly associated with increased mortality. Patients with cancer and COVID-19 had higher severity scores (P&lt;0.003), longer ventilation duration (P&lt;0.002), and ICU stay (P&lt;0.002).<jats:bold> <\/jats:bold>Overall mortality was 45%.8, there was no significant difference in mortality rate between patients with solid organ tumors and hematological malignancy with COVID-19 infection requiring intensive care therapy (P&lt;0.68).\n<jats:bold>Conclusion: <\/jats:bold>Cancer patients requiring ICU were more prone to develop AKI, rhabdomyolysis, secondary infection, requiring ventilation and prone position, and septic shock. These patients had a significantly high mortality rate and were severely ill, requiring prolonged ventilation and ICU stays.<\/jats:p>","DOI":"10.21203\/rs.3.rs-2779474\/v1","type":"posted-content","created":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T23:58:43Z","timestamp":1681689523000},"source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 in Patients with Cancer: Insights from a Tertiary Care Intensive Care Unit"],"prefix":"10.21203","author":[{"given":"Nissar","family":"Shaikh","sequence":"first","affiliation":[{"name":"Hamad Medical Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Al","family":"Wraidat","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anood A.","family":"Al-Assaf","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma K.","family":"Al-Kaabi","sequence":"additional","affiliation":[{"name":"Ministry of Public Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad A.","family":"Abujaber","sequence":"additional","affiliation":[{"name":"Hazm Mebaireek General Hospital, Hamad Medical Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samar","family":"Jasim","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salha","family":"Bujassoum","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muna A.","family":"Almaslamani","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad Y.","family":"Khatib","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulqadir J.","family":"Nashwan","sequence":"additional","affiliation":[{"name":"Hazm Mebaireek General Hospital, Hamad Medical Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8761","reference":[{"issue":"1","key":"ref1","first-page":"1","article-title":"Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis","volume":"13","author":"-Meng Y","unstructured":"-Meng Y, Lu W, Guo E, Liu J, Yang B, Wu P, Lin S, Peng T, Fu Y, Li F, Wang Z. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis. J Hematol Oncol. 2020 Dec;13(1):1\u20131.","journal-title":"J Hematol Oncol"},{"issue":"33","key":"ref2","first-page":"3914","article-title":"COVID-19 Severity and Outcomes in Patients with Cancer: A Matched Cohort Study","volume":"20","author":"-Brar G","unstructured":"-Brar G, Pinheiro LC, Shusterman M, Swed B, Reshetnyak E, Soroka O, Chen F, Yamshon S, Vaughn J, Martin P, Paul D, Hidalgo M, Shah MA. COVID-19 Severity and Outcomes in Patients with Cancer: A Matched Cohort Study. J Clin Oncol. 2020 Nov;20(33):3914\u201324.","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00277-020-04328-4","article-title":"LEOSS Study Group. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry","volume":"100","author":"-R\u00fcthrich MM","unstructured":"-R\u00fcthrich MM, Giessen-Jung C, Borgmann S, Classen AY, Dolff S, Gr\u00fcner B, Hanses F, Isberner N, K\u00f6hler P, Lanznaster J, Merle U, Nadalin S, Piepel C, Schneider J, Schons M, Strauss R, Tometten L, Vehreschild JJ, von Lilienfeld-Toal M, Beutel G, Wille K. LEOSS Study Group. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry. Ann Hematol. 2021 Feb;100(2):383\u201393.","journal-title":"Ann Hematol"},{"key":"ref4","author":"-Kim Y","unstructured":"-Kim Y, Zhu L, Zhu H, Li X, Huang Y, Gu C, Bush H, Chung C, Zhang GQ. Characterizing cancer and COVID-19 outcomes using electronic health records.PLoS One. 2022 May4;17(5):e0267584."},{"key":"ref5","first-page":"1286","article-title":"Mortality in Cancer Patients With COVID-19 Who Are Admitted to an ICU or Who Have Severe COVID-19: A Systematic Review and Meta-Analysis","volume":"7","author":"-Nadkarni AR","unstructured":"-Nadkarni AR, Vijayakumaran SC, Gupta S, Divatia JV. Mortality in Cancer Patients With COVID-19 Who Are Admitted to an ICU or Who Have Severe COVID-19: A Systematic Review and Meta-Analysis. JCO Glob Oncol. 2021 Aug;7:1286\u2013305.","journal-title":"JCO Glob Oncol"},{"key":"ref6","author":"-Brar G","unstructured":"-Brar G, Pinheiro LC, Shusterman M, Swed B, Reshetnyak E, Soroka O, Chen F, Yamshon S, Vaughn J, Martin P, Paul D. COVID-19 severity and outcomes in patients with cancer: a matched cohort study.Journal of Clinical Oncology. 2020 Nov20;38(33):3914."},{"key":"ref7","author":"-Joerger M","year":"2022","unstructured":"-Joerger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt AM, Cantoni N, Caspar CB, Stettler S, Malval R. Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80\/20 (CaSA). Cancers. 2022 Apr 27;14(9):2191."},{"issue":"10241","key":"ref8","first-page":"1907","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"20","author":"-Kuderer NM","unstructured":"-Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. The Lancet. 2020 Jun;20(10241):1907\u201318.","journal-title":"The Lancet"},{"key":"ref9","author":"-Fong D","year":"2020","unstructured":"-Fong D, Rauch S, Petter C, Haspinger E, Alber M, Mitterer M. Infection rate and clinical management of cancer patients during the COVID-19 pandemic: experience from a tertiary care hospital in northern Italy. ESMO open. 2020 Jan 1;5(3):e000810."},{"key":"ref10","author":"-Peng M","unstructured":"-Peng M, He J, Xue Y, Yang X, Liu S, Gong Z. Role of Hypertension on the Severity of COVID-19: A Review. J Cardiovasc Pharmacol. 2021 Nov 1;78(5):e648-e655."},{"key":"ref11","first-page":"1","article-title":"Bacterial infections and antibiotic utilization varies by coronavirus disease 19 (COVID-19) severity in hospitalized cancer patients: Analysis from the first phase of the pandemic","volume":"26","author":"-Maki KR","unstructured":"-Maki KR, Steiger SN, Su Y, Boumiza A, Tan CA, Kerpelev M, Seo SK, Cohen N. Bacterial infections and antibiotic utilization varies by coronavirus disease 19 (COVID-19) severity in hospitalized cancer patients: Analysis from the first phase of the pandemic. Infect Control Hosp Epidemiol. 2022 May;26:1\u20137.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"ref12","first-page":"e6","article-title":"Secondary infections in a cohort of patients with COVID-19 admitted to an intensive care unit: impact of gram-negative bacterial resistance","volume":"2","author":"-Costa RLD","unstructured":"-Costa RLD, Lamas CDC, Simvoulidis LFN, Espanha CA, Moreira LPM, Bonancim RAB, Weber JVLA, Ramos MRF, Silva ECF, Oliveira LP. Secondary infections in a cohort of patients with COVID-19 admitted to an intensive care unit: impact of gram-negative bacterial resistance. Rev Inst Med Trop Sao Paulo. 2022 Feb;2:64: e6.","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"ref13","author":"-Pathania AS","unstructured":"-Pathania AS, Prathipati P, Abdul BA, Chava S, Katta SS, Gupta SC, Gangula PR, Pandey MK, Durden DL, Byrareddy SN, Challagundla KB. COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges.2021 Jan 1;11(2):731\u2013753."},{"issue":"1","key":"ref14","first-page":"540","article-title":"Biomarkers for Prognosis and Treatment Response in COVID-19 Patients","volume":"41","author":"-Bivona G","unstructured":"-Bivona G, Agnello L, Ciaccio M. Biomarkers for Prognosis and Treatment Response in COVID-19 Patients. Ann Lab Med. 2021 Nov;41(1):540\u20138.","journal-title":"Ann Lab Med"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1002\/hsr2.542","article-title":"Predictors of mortality and morbidity in critically ill COVID\u201019 patients: An experience from a low mortality country","volume":"5","author":"-Khatib MY","unstructured":"-Khatib MY, Ananthegowda DC, Elshafei MS, El-Zeer H, Abdaljawad WI, Shaheen MA, Ibrahim AS, Abujaber AA, Soliman AA, Mohamed AS, Al\u2010Wraidat M. Predictors of mortality and morbidity in critically ill COVID\u201019 patients: An experience from a low mortality country. Health Sci Rep. 2022 May;5(3):e542.","journal-title":"Health Sci Rep"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2779474\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2779474\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T03:30:36Z","timestamp":1698809436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2779474\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":15,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-2779474\/v1","relation":{},"subject":[],"published":{"date-parts":[[2023,4,17]]},"subtype":"preprint"}}